The Global Influenza Market

Published - Sep 2009| Analyst - Melissa Elder| Code - PHM049B
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • Overall sales in the global influenza market were worth $5.3 billion in 2007, which declined to $3.7 billion in 2008, then increased to an estimated $5.5 billion in 2009. By 2014, it is projected to increase to $6.3 billion, for a 5-year CAGR of 2.7%.
  • The largest segment of the market, vaccines, was valued at $2.8 billion in 2008; this is expected to increase to $3.2 billion in 2009, and is projected to reach $4.2 billion in 2014, for a 5-year CAGR of 5.6%.
  • Sales in the therapeutics market amounted to $701 million in 2008, increased to an estimated $2.1 billion in 2009, and are expected to fall to $1.9 billion in 2014, for a 5-year CAGR of -2.4%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, The Global Influenza Market: Vaccines, Therapeutics, and Diagnostics is an update to the BCC Research report published in 2006 titled, The Worldwide Influenza Market (PHM049A). This report provides an overview of products currently in the marketplace and a detailed analysis of market position and competitive environments. The study includes information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers. There is a special emphasis on U.S. and European markets.

REASONS FOR DOING THE STUDY
 
Annually, up to a half–million people die of influenza and, with the threat of a pandemic, government agencies and disease prevention organizations are devoted to gaining control of the situation. Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next 5 years will continue to display support and funding for many research and development programs, product development and pandemic prevention and/or control by worldwide governments, organizations, and health professionals. 
 
SCOPE OF REPORT
 
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. data. The report identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts, and competitive analyses. Additionally, the study covers some of the most significant issues and trends and market factors.
 
METHODOLOGY
 
The information for this BCC report was obtained through primary and secondary data collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, government departments, and other key representatives involved in the influenza industry. Secondary methods included published literature, investment reports, company literature, and various business journals that have emphasis on influenza products, technology and related information.
 
Market data for this report pertains to the worldwide market, with specific U.S. data included. All information is displayed using U.S. dollars at the manufacturers’ level. The base year of the report is 2009, with historical data provided for 2007 and 2008, and forecast data provided through 2014. Historical, base year, and forecast data are provided for each market segment of the report. Compound annual growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, current product growth, and government intervention and stockpiling trends. Competitor market share estimates are provided for each market segment for the 2009 base year.
 
ANALYST CREDENTIALS
 
Melissa Elder is an experienced healthcare market analyst, specializing in prescription and over–the–counter pharmaceuticals, medical devices, animal health products, and emerging healthcare technologies. Ms. Elder has more than 13 years of experience in the healthcare industry, specializing in market research for the past 10 years. This experience has given her substantial insight into pharmaceutical market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets. 
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - May-2006| Analyst - Melissa Elder| Code - PHM049A

Report Highlights

  • By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.
  • The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.
  • The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.
  • The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report